Abstract
Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer is associated with decreased overall survival. Trastuzumab, a humanized monoclonal antibody that targets HER2, is approved by the Food and Drug Administration for patients with invasive breast cancers that overexpress HER2. This review considers the mechanism of action and the use of this agent.
Keywords
TrastuzumabMedicineMechanism of actionMonoclonal antibodyBreast cancerMonoclonalMechanism (biology)Food and drug administrationOncologyDrugEpidermal growth factor receptorCancerHuman Epidermal Growth Factor Receptor 2PharmacologyInternal medicineAntibodyImmunology
Affiliated Institutions
Related Publications
Trastuzumab-Induced Hepatotoxicity: A Case Report
<b><i>Background: </i></b>Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overe...
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Aims: Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is implicated in the development of various solid tumour types. Validated methods and scoring ...
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
PURPOSE Breast cancer frequently overexpresses the product of the HER2 proto-oncogene, a 185-kd growth factor receptor (p185HER2). The recombinant humanized monoclonal antibody ...
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer...
Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC)
764 Background: Overexpression of the HER2 receptor protein predicts a worse prognosis and higher metastatic risk in patients (pts) with breast cancer. HER2 positivity also has ...
Publication Info
- Year
- 2007
- Type
- review
- Volume
- 357
- Issue
- 1
- Pages
- 39-51
- Citations
- 2525
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
2525
OpenAlex
Cite This
Clifford A. Hudis
(2007).
Trastuzumab — Mechanism of Action and Use in Clinical Practice.
New England Journal of Medicine
, 357
(1)
, 39-51.
https://doi.org/10.1056/nejmra043186
Identifiers
- DOI
- 10.1056/nejmra043186